Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Gene expression in blood is associated with risperidone response in children with autism spectrum disorders

The Pharmacogenomics Journal volume 12, pages 368–371 (2012)Cite this article

Subjects

Abstract

Children with autism spectrum disorders (ASDs) often have severe behavioral problems. Not all children with these problems respond to atypical antipsychotic medications; therefore, we investigated whether peripheral blood gene expression before treatment with risperidone, an atypical antipsychotic, was associated with improvements in severe behavioral disturbances 8 weeks following risperidone treatment in 42 ASD subjects (age 112.7±51.2 months). Exon expression levels in blood before risperidone treatment were compared with pre–post risperidone change in Aberrant Behavior Checklist-Irritability (ABC-I) scores. Expression of exons within five genes was correlated with change in ABC-I scores across all risperidone-treated subjects: GBP6, RABL5, RNF213, NFKBID and RNF40 (α<0.001). RNF40 is located at 16p11.2, a region implicated in autism and schizophrenia. Thus, these genes expressed before treatment were associated with subsequent clinical response. Future studies will be needed to confirm these results and determine whether this expression profile is associated with risperidone response in other disorders, or alternative antipsychotic response within ASD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. des Portes V, Hagerman RJ, Hendren RL . Pharmacotherapy. In: Ozonoff S, Rogers SJ, Hendren RL (eds). Autism Spectrum Disorders: A Research Review for Practitioners. American Psychiatric Association Publishing: Washington, DC, 2003, pp 161–186.

    Google Scholar 

  2. Williams SK, Scahill L, Vitiello B, Aman MG, Arnold LE, McDougle CJ et al. Risperidone and adaptive behavior in children with autism. J Am Acad Child Adolescent Psychiatry 2006; 45: 431–439.

    Article  Google Scholar 

  3. Bantick RA, Deakin JF, Grasby PM . The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 2001; 15: 37–46.

    Article  CAS  PubMed  Google Scholar 

  4. Ichikawa J, Meltzer HY . Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci 1999; 249 (Suppl 4): 90–98.

    Article  PubMed  Google Scholar 

  5. Swann AC . Neuroreceptor mechanisms of aggression and its treatment. J Clin Psychiatry 2003; 64 (Suppl 4): 26–35.

    CAS  PubMed  Google Scholar 

  6. Tarazi FI, Zhang K, Baldessarini RJ . Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2001; 297: 711–717.

    CAS  PubMed  Google Scholar 

  7. McDougle CJ, Hollway J, Scahill L, Koenig K, Aman MG, McGough JJ et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005; 162: 1142–1148.

    Article  PubMed  Google Scholar 

  8. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347: 314–321.

    Article  CAS  PubMed  Google Scholar 

  9. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114: E634–E641.

    Article  PubMed  Google Scholar 

  10. Pandina GJ, Bossie CA, Zhu Y, Flanders S . The aberrant behavior checklist: use in clinical trials of pediatric autism. J Child Adolescent Psychopharmacol 2006; 16: 661–662.

    Article  Google Scholar 

  11. Posey DJ, McDougle CJ . The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry 2000; 8: 45–63.

    Article  CAS  PubMed  Google Scholar 

  12. Su KP, Wu PL, Pariante CM . A cross-over study on safety of lipid profiles associated with olanzapine and risperidone. Eur Neuropsychopharmacol 2005; 15: S463–S464.

    Google Scholar 

  13. Danielyan A, Kowatch RA . Management options for bipolar disorder in children and adolescents. Paediatr Drugs 2005; 7: 277–294.

    Article  PubMed  Google Scholar 

  14. Bottai T, Quintin P, Perrin E . Antipsychotics and the risk of diabetes: a general data review. Eur Psychiatry 2005; 20 (Suppl 4): S349–S357.

    Article  PubMed  Google Scholar 

  15. McKee JR, Bodfish JW, Mahorney SL, Heeth WL, Ball MP . Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. J Clin Psychiatry 2005; 66: 1161–1168.

    Article  CAS  PubMed  Google Scholar 

  16. Erickson CA, Stigler KA, Posey DJ, McDougle CJ . Risperidone in pervasive developmental disorders. Expert Rev Neurother 2005; 5: 713–719.

    Article  CAS  PubMed  Google Scholar 

  17. Stamova B, Xu H, Jickling G, Bushnell C, Tian Y, Ander BP et al. Gene expression profiling of blood for the prediction of ischemic stroke. Stroke 2010; 41: 2171–2177.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Sollner T, Bennett MK, Whiteheart SW, Scheller RH, Rothman JE . A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion. Cell 1993; 75: 409–418.

    Article  CAS  PubMed  Google Scholar 

  19. Muller DJ, Klempan TA, De Luca V, Sicard T, Volavka J, Czobor P et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 2005; 379: 81–89.

    Article  PubMed  Google Scholar 

  20. Haase J, Killian AM, Magnani F, Williams C . Regulation of the serotonin transporter by interacting proteins. Biochem Soc Trans 2001; 29 (Part 6): 722–728.

    Article  CAS  PubMed  Google Scholar 

  21. Hanson E, Nasir RH, Fong A, Lian A, Hundley R, Shen Y et al. Cognitive and behavioral characterization of 16p11.2 deletion syndrome. J Dev Behav Pediatr 2010; 31: 649–657.

    Article  PubMed  Google Scholar 

  22. Shen Y, Dies KA, Holm IA, Bridgemohan C, Sobeih MM, Caronna EB et al. Clinical genetic testing for patients with autism spectrum disorders. Pediatrics 2010; 125: e727–e735.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Vassos E, Collier DA, Holden S, Patch C, Rujescu D, St Clair D et al. Penetrance for copy number variants associated with schizophrenia. Hum Mol Genet 2010; 19: 3477–3481.

    Article  CAS  PubMed  Google Scholar 

  24. Borden KL, Freemont PS . The RING finger domain: a recent example of a sequence-structure family. Curr Opin Struct Biol 1996; 6: 395–401.

    Article  CAS  PubMed  Google Scholar 

  25. Sunderman Jr FW . The clinical biochemistry of 5′-nucleotidase. Ann Clin Lab Sci 1990; 20: 123–139.

    PubMed  Google Scholar 

  26. Arnold LE, Farmer C, Kraemer HC, Davies M, Witwer A, Chuang S et al. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adolesc Psychopharmacol 2010; 20: 83–93.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Correia CT, Almeida JP, Santos PE, Sequeira AF, Marques CE, Miguel TS et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J 2010; 10: 418–430.

    Article  CAS  PubMed  Google Scholar 

  28. Ikeda M, Tomita Y, Mouri A, Koga M, Okochi T, Yoshimura R et al. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol Psychiatry 2010; 67: 263–269.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We appreciate the participation of study volunteers and their families. This study was supported by R21MH080026 (RLH).

Author information

Authors and Affiliations

  1. Department of Neurology, University of California, Davis, MIND Institute, Davis, CA, USA

    L Lit, F R Sharp, B Stamova & B P Ander

  2. University of California, Irvine, School of Medicine,

    K Bertoglio

  3. University of California, San Francisco, School of Medicine, San Francisco, CA, USA

    A D Sossong

  4. Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA

    R L Hendren

Authors
  1. L Lit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F R Sharp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Bertoglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Stamova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B P Ander
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A D Sossong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R L Hendren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Lit.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website

Supplementary information

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lit, L., Sharp, F., Bertoglio, K. et al. Gene expression in blood is associated with risperidone response in children with autism spectrum disorders. Pharmacogenomics J 12, 368–371 (2012). https://doi.org/10.1038/tpj.2011.23

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2011.23

Keywords

This article is cited by

Search

Advanced search

Quick links